Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
1
institution
Market cap
$75.5M
93M shares
52-week range
$0.49 β $2.25
18% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
www.citiusonc.comNo one on the platform currently holds CTOR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 55,900 | $113.5K |
No one on the platform has traded CTOR yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CTOR 5 hours for the financials to be released, and absolutely no one is interested in CTOR based on the trading. Kinda says everything. Of course the standard excuse is investors are just waiting.However to me investors do not expect much.
View on StockTwits β$CTOR $CTXR Previous quarter ended on June 30. 10-Q filings for non-accelerated filers are due today, 45 days after the end of the quarter. Last week, CTOR issued a PR to highlight that institutions ordering LYMPHIR increased by 78%. But it appears they are going to wait until AH on a Friday, the last day to file the 10-Q, before they disclose the actual revenue numbers. Classic Leonard π
View on StockTwits β$CTOR Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri https://www.prnewswire.com/news-releases/citius-oncology-expands-board-with-appointment-of-independent-director-jonathan-peri-302849254.html
View on StockTwits β$CTOR Buy rating reaffirmed.$$4 price target and commercial sales booming.....tick tock
View on StockTwits β$CTOR $4.X Price target maintained. Trading at under 20% of the value. Time to load up?
View on StockTwits β$CTOR this has to clear a dollar by eow, right? Business is goodβ¦
View on StockTwits βπ Top Penny Stock Movers by Relative Volume $FLZH β 18.01x RVOL Move: +16% Volume: 4.1M (227.9K average) Market Cap: $1.8M Day Range: 1.11 β 1.44 52-Week Range: 1.11 β 37.00 $KLTR β 8.71x RVOL Move: +38% Volume: 4.2M (477.1K average) Market Cap: $289.5M Day Range: 1.43 β 1.96 52-Week Range: 1.05 β 2.01 $CTOR β 8.52x RVOL Move: +14% Volume: 696.0K (81.7K average) Market Cap: $70.7M Day Range: 0.63 β 0.89 52-Week Range: 0.49 β 2.25 Momentum and unusual volume are driving attention. Which one are you watching? π Not financial advice.
View on StockTwits β$CTOR Up 26% today and still way undervalued. Come join the fun!!
View on StockTwits β$CTOR highlights a growing base of institutional accounts ordering LYMPHIR.
View on StockTwits β$CTOR Citius Oncology announced a strong 78% quarter-over-quarter (QoQ!!!!) increase in medical accounts ordering LYMPHIR, expanding its footprint across 42 top US cancer centers and regional clinics. This commercial momentum is driven by rising repeat vial orders from healthcare providers alongside near 100% insurer coverage ahead of their full sales force rollout. https://finance.yahoo.com/healthcare/articles/citius-oncology-reports-strong-commercial-131700198.html
View on StockTwits β$CTOR Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
View on StockTwits β$CTOR Even though the financials will not be released untill late next week, the results are are known with management in the company. So what ever happens now till the release may inducate how the results will be, since there are always leaks that occur. However with Mazur's history in reality you cannot expect any great news.
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $21M | -27.4% | $-0.52 | $-0.52β$-0.52 | β | 1 |
| 2027 | $95M | +357.0% | $0.10 | $0.10β$0.10 | 8.1Γ | 1 |
| 2028 | $157M | +65.4% | $0.46 | $0.46β$0.46 | 1.8Γ | 1 |
| 2029 | $177M | +12.5% | $0.53 | $0.53β$0.53 | 1.5Γ | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 3 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | $-0.01 | $-0.27 | -2600.0% |
| 2026-02-13 | $-0.04 | $-0.06 | -50.0% |
| 2025-12-23 | $-0.06 | $-0.06 | +0.0% |
| 2025-08-12 | $-0.15 | $-0.08 | +46.7% |
| 2025-05-14 | $-0.09 | $-0.11 | -22.2% |
| 2025-02-14 | $-0.06 | $-0.09 | -50.0% |
| 2024-12-27 | $-0.08 | $-0.07 | +10.3% |
| $1.6B |
| β |
| LNSRLENSAR Inc | $8.25 | -0.24% | $101M | β |
| MCRBSeres Therapeutics, Inc. | $4.47 | -0.22% | $43M | β |
Source: Financial Modeling Prep Β· peers by sector/industry